Digital Therapeutics: Regulatory Pathways in Asia
Digital therapeutics regulatory pathways in Asia are evolving rapidly — from Japan’s nine approved products and national reimbursement inclusion to China’s USD 2.8 million China-specific trial requirements. This in-depth analysis covers the regulatory frameworks, clinical evidence standards, approval timelines, and market data shaping how digital therapeutics reach patients across Japan, South Korea, China, and Southeast Asia.
Cell & Gene Therapy: Regulatory Landscape Across Asia
The cell and gene therapy regulatory landscape across Asia is evolving at remarkable speed — from China’s NMPA Fast Track cutting review times to 60 working days, to Japan’s SAKIGAKE pathway delivering approvals in six months. This in-depth analysis examines approval frameworks, timelines, and strategic considerations across China, Japan, South Korea, Singapore, and Australia for advanced therapy developers navigating Asia-Pacific market access in 2026.
Blockchain in Pharmaceutical Supply Chains: Hype or Help?
Blockchain in pharmaceutical supply chains promises end-to-end traceability and counterfeit prevention — but does the real-world data support the hype? With counterfeit pharma trade valued at USD 4.4 billion annually, verification cycle times cut by 99% in mature deployments, and ROI reaching 340% for fully integrated implementations, this in-depth analysis examines where blockchain genuinely delivers, where it underperforms, and what separates successful adoption from expensive disappointment.
Mainland China to Hong Kong: Cross-Border Pharmaceutical Considerations
Navigating Mainland China to Hong Kong cross-border pharmaceutical considerations requires understanding two separate regulatory frameworks, distinct GMP and labelling requirements, and a supply chain landscape where 47% of import delays stem from documentation errors alone — this in-depth guide covers everything pharmaceutical companies need to know to achieve compliant, efficient cross-border market access.
Real-World Evidence (RWE) in Pharmaceutical Decision-Making
Real-world evidence in pharmaceutical decision-making is reshaping how drugs are approved, priced, and monitored globally — with RWE now included in 67% of EMA submissions and products supported by robust RWE achieving reimbursement rates 23% higher than trial-only submissions. This in-depth guide explains what RWE is, where it matters most, and how pharmaceutical companies can build a credible RWE strategy that delivers regulatory and commercial results.
Bioequivalence Studies for Generic Drugs: A Beginner’s Guide
Bioequivalence studies are the scientific foundation behind every approved generic drug — but how do they actually work, and why do nearly 40% of first-cycle submissions fail? This beginner’s guide explains the 80–125% rule, BCS biowaivers, regulatory requirements across key Asian and global markets, and the real cost of getting your bioequivalence study design wrong.
Orphan Drugs & Rare Disease Pathways in Asia
Asia is home to an estimated 60 million people living with rare diseases — yet 38% have no approved treatment available in any Asian market. This data-driven guide covers orphan drug regulatory pathways across Japan, China, South Korea, Taiwan, and Southeast Asia, the reimbursement landscape, and the strategic opportunities that the region’s rapidly evolving rare disease frameworks are creating for sponsors with orphan drugs in development or already approved elsewhere.
Decentralised Clinical Trials (DCTs): Opportunities for Asia
Decentralised clinical trials in Asia are growing at nearly twice the global average rate — with DCT designs delivering 43% faster recruitment, 31% lower screen failure rates, and access to patient populations that conventional site-based models have never reached. This data-driven guide covers the regulatory landscape across Japan, China, South Korea, and Southeast Asia, the technology infrastructure realities, and the strategic opportunity that Asian DCTs represent for global drug development programmes.
AI in Drug Discovery: How It’s Changing the Pharmaceutical Landscape
AI in drug discovery is delivering measurable results — with AI-assisted programmes reducing time to clinical candidate nomination by 49%, cutting preclinical costs by 56%, and driving USD 8.9 billion in global investment in 2024 alone. This data-driven guide covers what AI actually does in pharmaceutical research, from AlphaFold protein structure prediction to generative molecular design and AI-assisted clinical trial stratification, and what the pipeline and investment data reveals about where the industry is heading.
The Common Technical Document (CTD): Structure & Submission Tips
The Common Technical Document (CTD) is the internationally harmonised format that determines how efficiently a pharmaceutical product reaches regulatory approval — with 43% of Asian market submissions receiving major deficiency notices, 61% of those deficiencies attributable to document quality rather than science, and approval delays averaging 14.3 months at a cost of USD 4.2 million per product, this data-driven guide covers the five-module CTD structure, eCTD digital submission requirements, and the practical submission tips that consistently separate first-cycle approvals from costly regulatory delays.